Compare NBN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | GERN |
|---|---|---|
| Founded | 1872 | 1990 |
| Country | United States | United States |
| Employees | 234 | 258 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.0M |
| IPO Year | N/A | N/A |
| Metric | NBN | GERN |
|---|---|---|
| Price | $125.57 | $1.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $130.50 | $2.17 |
| AVG Volume (30 Days) | 115.9K | ★ 8.7M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.77 | $26.91 |
| Revenue Next Year | $18.72 | $43.75 |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.75 | $1.04 |
| 52 Week High | $142.31 | $2.01 |
| Indicator | NBN | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 38.42 |
| Support Level | $127.84 | $1.24 |
| Resistance Level | $138.66 | $1.30 |
| Average True Range (ATR) | 5.66 | 0.08 |
| MACD | -0.73 | -0.02 |
| Stochastic Oscillator | 48.31 | 16.13 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.